Watch LCTX. Know when insiders buy.
One email the day a filing lands. Free.
LCTX
Lineage Cell Therapeutics, Inc.
1.03
+0.00 +0.00%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
44
WATCH · shorts 44
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $260.5MP/E —DIV YIELD —FCF YIELD -9.36%REV TTM $13.1M +19.9%NET INCOME −$32.3MNET CASH $37.3M52W 1.01 – 1.96SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.1M | −61.3% | — | −$8.9M | $1.5M | — | -0.03 | −$7.2M | $108K | −$7.4M | Aug 6 |
| Q1 2026 · Mar 31 | $1.7M | +14.8% | — | −$7.6M | −$4.8M | — | -0.03 | −$8.1M | $55K | −$8.1M | May 12 |
| Q4 2025 · Dec 31derived | $6.6M | +130.4% | — | −$6.5M | $851K | — | 0.00 | −$4.9M | $399K | −$5.3M | Mar 5 |
| Q3 2025 · Sep 30 | $3.7M | −2.6% | — | −$3.8M | −$29.8M | — | -0.13 | −$3.6M | $12K | −$3.6M | Nov 6 |
| Q2 2025 · Jun 30 | $2.8M | +96.4% | — | −$19.8M | −$30.5M | — | -0.13 | −$5.5M | $14K | −$5.6M | Aug 6 |
| Q1 2025 · Mar 31 | $1.5M | +4.0% | 97.6% | −$6.5M | −$4.1M | — | -0.02 | −$4.9M | $97K | −$5M | May 12 |
| Q4 2024 · Dec 31derived | $2.9M | +37.4% | 94.6% | −$5.1M | −$3.3M | — | -0.01 | −$6.3M | $365K | −$6.7M | Mar 5 |
| Q3 2024 · Sep 30 | $3.8M | +203.3% | 99.0% | −$3.8M | −$3M | — | -0.02 | −$5.8M | $112K | −$5.9M | Nov 6 |
| Q2 2024 · Jun 30 | $1.4M | — | 96.9% | −$5.9M | −$5.8M | — | -0.03 | −$5.2M | $50K | −$5.2M | Aug 12 |
| Q1 2024 · Mar 31 | $1.4M | — | 93.2% | −$6.7M | −$6.5M | — | -0.04 | −$5.8M | $38K | −$5.8M | May 13 |
| Q4 2023 · Dec 31 | $2.1M | — | 87.7% | −$6.4M | −$4.8M | — | -0.03 | −$6M | $91K | −$6.1M | Mar 10 |
| Q3 2023 · Sep 30 | $1.2M | — | 86.4% | −$6.7M | −$7.1M | — | -0.04 | −$5M | $139K | −$5.2M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $14.6M | — | −$36.6M | −$63.5M | -436.5% | -0.28 | −$18.9M | $522K | −$19.4M | — | — |
| FY2024 · to Dec 31 | $9.5M | 96.5% | −$21.5M | −$18.6M | -195.9% | -0.09 | −$23.1M | $565K | −$23.7M | — | — |
| FY2023 · to Dec 31 | $8.9M | 92.5% | −$24.7M | −$21.5M | -240.2% | -0.12 | −$28.6M | $674K | −$29.2M | — | — |
| FY2022 · to Dec 31 | $14.7M | 95.0% | −$22.5M | −$26.3M | -178.7% | -0.15 | $1.1M | $413K | $646K | — | — |
| FY2021 · to Dec 31 | $4.3M | 67.2% | −$49.2M | −$43M | -991.0% | -0.26 | −$23.6M | $340K | −$23.9M | — | — |
| FY2020 · to Dec 31 | $1.8M | 78.9% | −$26.4M | −$20.6M | -1130.8% | -0.14 | −$19.8M | $64K | −$19.8M | — | — |
Every number comes from Lineage Cell Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.